Publications by authors named "R Manes"
Trends in Medicare Utilization and Reimbursement of Tracheostomy From 2000 to 2022.
Otolaryngol Head Neck Surg
November 2024
Objective: To analyze the utilization and reimbursement for tracheostomy.
Study Design: Retrospective Cross-Sectional Study.
Setting: Centers for Medicare & Medicaid Services (CMS) Medicare Provider Utilization and Payment Data (2013 and 2021) and Part B Medicare Fee-For-Service National Summary Data (2000-2022).
Article Synopsis
- The study investigates trends in soft palate surgery for obstructive sleep apnea (OSA) from 2000 to 2021 using Medicare data, focusing on trends in procedure usage and reimbursement.
- Overall surgeries decreased by 65.7%, with traditional uvulopalatopharyngoplasty (UPPP) dropping 87.6%, while pharyngoplasty (PP) rose by 245.4%.
- Total Medicare payments for these procedures fell significantly by 57.2%, with a notable decrease in UPPP reimbursements, highlighting a shift in preferences toward less invasive options like PP.
A rare case of disseminated amebiasis in a patient on biologic therapy for chronic rhinosinusitis.
Int Forum Allergy Rhinol
January 2025
Article Synopsis
- Dupilumab is a medication that focuses on Th2-related inflammation to help lessen symptoms in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).
- Although uncommon, using Dupilumab can lead to certain infections, including those caused by viruses, worms (helminths), and possibly amoebas.
- The aim of Dupilumab is to improve health outcomes for individuals suffering from this specific type of nasal condition.
Characterizing the Rise in Dupilumab Prescriptions and Costs: A Medicare Part D Study.
Otolaryngol Head Neck Surg
January 2025
Article Synopsis
- Dupilumab, approved by the FDA in 2017, has seen an increase in prescribers and claims in Medicare from 2017 to 2021, with prescribers rising from 142 to 6,244 and claims growing from 2,444 to 157,401.
- The financial implications are significant, with costs escalating from $7.59 million to $540.5 million over the same period.
- While dermatologists initially dominated prescribing, their share dropped from 78.9% in 2017 to 38.1% in 2021, indicating a diversification in the types of medical professionals prescribing dupilumab as its uses expanded.
Background: Accurate conflict of interest (COI) information is essential for promoting transparency and trust in research. We aim to assess COI disclosure patterns in monoclonal antibodies (MABs) research for chronic rhinosinusitis with nasal polyposis (CRSwNP) using the Open Payments Database (OPD).
Methods: Studies on FDA-approved MABs for CRSwNP (dupilumab, omalizumab, mepolizumab) published between 2019 and 2021 with at least one US author were identified through PubMed.